Gossamer Bio (NASDAQ:GOSS) Releases Earnings Results, Misses Estimates By $0.06 EPS

16 May 2026, 13:01 by Amy Steele · The Cerbat Gem

Gossamer Bio (NASDAQ:GOSS – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06), FiscalAI reports. The company had revenue of $16.96 million for the quarter, compared to analyst estimates of $4.67 million.

Gossamer Bio Trading Up 3.0%

Shares of Gossamer Bio stock traded up $0.01 during trading hours on Friday, reaching $0.34. The stock had a trading volume of 5,500,862 shares, compared to its average volume of 4,363,200. The firm has a market capitalization of $79.80 million, a price-to-earnings ratio of -0.45 and a beta of 2.15. Gossamer Bio has a 1 year low of $0.31 and a 1 year high of $3.87. The firm has a 50 day simple moving average of $0.39 and a two-hundred day simple moving average of $1.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Beacon Pointe Advisors LLC acquired a new position in shares of Gossamer Bio during the 4th quarter valued at $34,000. Ieq Capital LLC acquired a new stake in Gossamer Bio in the 4th quarter valued at $35,000. Janney Montgomery Scott LLC purchased a new position in Gossamer Bio in the fourth quarter valued at about $39,000. Cibc World Markets Corp purchased a new position in Gossamer Bio in the fourth quarter valued at about $39,000. Finally, O Shaughnessy Asset Management LLC acquired a new position in shares of Gossamer Bio during the fourth quarter worth about $41,000. 81.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on GOSS. Royal Bank Of Canada raised Gossamer Bio to an “outperform” rating in a research note on Tuesday, February 24th. HC Wainwright reduced their target price on Gossamer Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a research note on Tuesday, April 21st. Leerink Partners cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, The Goldman Sachs Group lowered shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Gossamer Bio currently has an average rating of “Hold” and an average price target of $5.00.

View Our Latest Report on Gossamer Bio

More Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

Negative Sentiment: Multiple law firms filed or publicized securities class-action claims against Gossamer Bio over allegations tied to the failed PROSERA study, highlighting legal overhang and potential damages risk for shareholders. Article: Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens Berman
Negative Sentiment: Law firms including Schall, Pomerantz, Rosen, Gross, Faruqi & Faruqi, and Bronstein are urging investors to join or lead the lawsuit, reinforcing concerns that the stock faces ongoing litigation risk and distraction. Article: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
Neutral Sentiment: Gossamer Bio said it will report first-quarter 2026 financial results and host a conference call on May 18, which may provide new guidance on cash runway, pipeline priorities, and management’s response to the trial setback. Article: Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

About Gossamer Bio

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.